PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer

Zhu, W; Xie, B

Xie, B (通讯作者),Cent South Univ, Xiangya Hosp, Dept Pathol, 87 Xiangya Rd, Changsha 410013, Peoples R China.

CANCER BIOLOGY & THERAPY, 2023; 24 (1):

Abstract

The anti-tumor effect of polo-like kinase 4 (PLK4) inhibitor has been explored in several solid carcinomas, while its application in anaplastic thyroi......

Full Text Link